senolytics
3 Longevity Science Trials That Could Outsmart Senescence
In 2024, Phase II trials reported a 62% reduction in senescent cell burden, indicating that three key longevity science studies are already outsmarting senescence. These trials combine genetic longevity formulas, senolytic drug combos, and bio-hacking protocols to target cellular aging. A breakthrough study claims senolytics can wipe out the cells
